Adenosine A2A Receptor Antagonist Therapy

Migration, Crosslink

📖

Adenosine A2A Receptor Antagonist Therapy

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-adenosine-a2a-receptor

📖 Wiki Page

therapeutic2036 wordssynced 2026-04-02

Adenosine A2A Receptor Antagonist Therapy

Overview

flowchart TD Adenosine_A2A_Receptor_Antagon["Adenosine A2A Receptor Antagonist Therapy"] Adenosine_A2A_Receptor_Antagon["Antagonist"] Adenosine_A2A_Receptor_Antagon -->|"related to"| Adenosine_A2A_Receptor_Antagon style Adenosine_A2A_Receptor_Antagon fill:#81c784,stroke:#333,color:#000 Adenosine_A2A_Receptor_Antagon["Therapy"] Adenosine_A2A_Receptor_Antagon -->|"related to"| Adenosine_A2A_Receptor_Antagon style Adenosine_A2A_Receptor_Antagon fill:#81c784,stroke:#333,color:#000 Adenosine_A2A_Receptor_Antagon["table"] Adenosine_A2A_Receptor_Antagon -->|"related to"| Adenosine_A2A_Receptor_Antagon style Adenosine_A2A_Receptor_Antagon fill:#81c784,stroke:#333,color:#000 style Adenosine_A2A_Receptor_Antagon fill:#4fc3f7,stroke:#333,color:#000

...

Adenosine A2A Receptor Antagonist Therapy

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2A Receptor Antagonist Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Koga et al., 2020</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">Xue et al., 2019</td>
<td>6-OHDA rats</td>
</tr>
<tr>
<td class="label">Pinna et al., 2021</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein) transgenic mice</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT00457465</td>
<td>Phase III</td>
</tr>
<tr>
<td class="label">NCT00470379</td>
<td>Phase III</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">Preladenant</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Vipadenant</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">KW-6002</td>
<td>Kyowa Hakko Kirin</td>
</tr>
<tr>
<td class="label">System</td>
<td>Adverse Event</td>
</tr>
<tr>
<td class="label">Central nervous system</td>
<td>Insomnia</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Constipation</td>
</tr>
<tr>
<td class="label">Psychiatric</td>
<td>Dyskinesia</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Palpitations</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M1.1 Lead optimization</td>
<td>Optimize A2A antagonists (istered but finite; current lead compounds show [BBB](/entities/blood-brain-barrier) penetration</td>
</tr>
<tr>
<td class="label">M1.2 iPSC neuronal assays</td>
<td>Test on patient-derived neurons (PD, AD) for anti-inflammatory effects</td>
</tr>
<tr>
<td class="label">M1.3 In vivo efficacy</td>
<td>MPTP and Abeta mouse models with motor/cognitive endpoints</td>
</tr>
<tr>
<td class="label">M1.4 GLP toxicology</td>
<td>28-day rat toxicology for lead A2A antagonist</td>
</tr>
<tr>
<td class="label">M1.5 IND package</td>
<td>CMC, pharmacology, toxicology compilation</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M2.1 Phase 1a SAD/MAD</td>
<td>Single/multiple ascending dose in healthy volunteers</td>
</tr>
<tr>
<td class="label">M2.2 Phase 1b</td>
<td>Early PD patients with levodopa, biomarker readouts</td>
</tr>
<tr>
<td class="label">M2.3 Biomarker validation</td>
<td>Cytokine panel (IL-1beta, TNF-alpha), motor assessments</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M3.1 Phase 2 RCT</td>
<td>Randomized controlled in 150 early PD patients with levodopa</td>
</tr>
<tr>
<td class="label">M3.2 Biomarker stratification</td>
<td>Genetic analysis, inflammatory markers</td>
</tr>
<tr>
<td class="label">M3.3 Long-term extension</td>
<td>12-month open-label safety</td>
</tr>
<tr>
<td class="label">Institution</td>
<td>Investigator</td>
</tr>
<tr>
<td class="label">University of Pennsylvania</td>
<td>Dr. John Nutt</td>
</tr>
<tr>
<td class="label">University of Bordeaux</td>
<td>Dr. Marc Laruelle</td>
</tr>
<tr>
<td class="label">Radboud University</td>
<td>Dr. R. Grond-Riether</td>
</tr>
<tr>
<td class="label">University of Cambridge</td>
<td>Dr. P. Jenner</td>
</tr>
<tr>
<td class="label">NIH/NINDS</td>
<td>Dr. B. Ravina</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Program</td>
</tr>
<tr>
<td class="label">Kyowa Hakko Kirin</td>
<td>Istradefylline (Nourianz)</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>A2A antagonists</td>
</tr>
<tr>
<td class="label">UCB Pharma</td>
<td>A2A/PDE1 dual inhibitors</td>
</tr>
<tr>
<td class="label">Novartis</td>
<td>A2A for PD</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>Neurology pipeline</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Likelihood</td>
</tr>
<tr>
<td class="label">Limited efficacy as monotherapy</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Competition from approved drugs</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cardiovascular effects</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Inflammatory target validation</td>
<td>Medium</td>
</tr>
</table>

Adenosine A2A Receptor Antagonist Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@koga2020]

Adenosine A2A receptor antagonists represent a novel non-dopaminergic therapeutic approach for neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) and potentially [Alzheimer's disease](/diseases/alzheimers-disease). Unlike traditional dopaminergic therapies, A2A antagonists work by modulating the adenosine receptor system, offering a different mechanism to improve motor symptoms while potentially providing neuroprotective effects. [@xue2019]

Mechanism of Action

Adenosine A2A Receptor Biology

The [adenosine A2A receptor](/proteins/a2a-adenosine-receptor) (ADORA2A) is a G protein-coupled receptor (GPCR) highly enriched in the [striatum](/brain-regions/striatum), specifically in indirect pathway medium spiny [neurons](/entities/neurons) (MSNs). These receptors are co-expressed with dopamine D2 receptors in striatopallidal neurons, creating a complex interplay between adenosine and dopamine signaling. [@pinna2021]

Key biological features: [@hauser2021]

Gs/olf protein coupling: A2A receptor activation stimulates adenylate cyclase, increasing cAMP levels
Striatal localization: Highest density in the caudate nucleus and putamen
Dopamine interaction: A2A and D2 receptors form heteromers with antagonistic interactions

A2A Blockade in the Basal Ganglia

The therapeutic mechanism involves: [@fernandez2020]

Striatal modulation: Blocking A2A receptors in the striatum reduces the excessive inhibition of motor output caused by adenosine-mediated signaling

Dopamine replacement synergy: A2A antagonists enhance the effect of levodopa without causing dyskinesias

Neuroinflammation reduction: A2A receptor activation promotes pro-inflammatory responses; antagonism reduces neuroinflammation

Effects on Motor Function

Improved motor scores: Clinical trials show significant improvements in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores
Reduced OFF time: Decreased "off" periods in patients with motor fluctuations
Dyskinesia management: Potential to reduce levodopa-induced dyskinesias through non-dopaminergic modulation

Preclinical Evidence

Parkinson's Disease Models

Multiple preclinical studies have demonstrated the efficacy of A2A antagonists in PD models: [@cunha2021]

Alzheimer's Disease Models

Emerging evidence suggests A2A antagonists may benefit AD: [@batalha2022]

[Amyloid-beta](/proteins/amyloid-beta) models: A2A blockade reduces amyloid-beta-induced neurotoxicity
[Tau](/proteins/tau) pathology: Reduced tau phosphorylation in preclinical models
Cognitive improvement: Enhanced memory performance in AD mouse models
Neuroinflammation: Decreased microglial activation and pro-inflammatory cytokines

Clinical Trial Status

FDA-Approved Compound

Istradefylline (Nourianz) — FDA approved in 2019 as an adjunct therapy to levodopa/carbidopa for adult patients with Parkinson's disease experiencing "off" episodes. [@sonsalla2019]

Compounds in Development

Current Clinical Trials

While development of several A2A antagonists has been discontinued, research continues:

Combination therapies: A2A antagonists with levodopa or other agents
Disease modification: Trials examining neuroprotective potential
Alzheimer's disease: Early-phase trials exploring cognitive benefits

Safety Profile

Common Adverse Effects

Contraindications and Precautions

Psychiatric disorders: Use with caution in patients with history of psychosis
Cardiac conditions: Monitor in patients with arrhythmias
Hepatic impairment: Dose adjustment may be required
Drug interactions: CYP1A2 inhibitors may increase exposure

Drug Interactions

CYP1A2 substrates: Istradefylline is a moderate CYP1A2 inhibitor
Theophylline: Avoid co-administration (both adenosine antagonists)
Anticoagulants: No significant interaction observed

Therapeutic Potential in Neurodegeneration

Parkinson's Disease

A2A antagonists offer several advantages in PD:

Non-dopaminergic mechanism: Works through adenosine modulation rather than dopamine replacement

Motor symptom improvement: Effective for bradykinesia and rigidity

OFF time reduction: Decreases periods of poor motor control

Dyskinesia potential: May reduce levodopa-induced dyskinesias

Alzheimer's Disease

The therapeutic potential in AD is under investigation:

Cognitive enhancement: Preclinical evidence suggests memory improvement
Neuroprotection: Reduced amyloid-beta and tau pathology in models
Anti-inflammatory: Decreased neuroinflammation
Combination potential: May enhance effects of [cholinesterase inhibitors](/entities/cholinesterase-inhibitors)

[Adenosine A2A Receptor](/proteins/a2a-adenosine-receptor) — Target receptor
[Adenosine A2A Receptor Neurons](/cell-types/adenosine-a2a-receptor-neurons) — Cell type expressing A2A
[Adenosine Signaling in Neurodegeneration](/mechanisms/adenosine-signaling-neurodegeneration) — Related mechanism
[Parkinson's Disease](/diseases/parkinsons-disease) — Primary indication
[Alzheimer's Disease](/diseases/alzheimers-disease) — Potential indication
[Istradefylline (Nourianz](/therapeutics/istradefylline) — FDA-approved drug
[Dopamine Receptors](/proteins/dopamine-receptor-family) — Related receptor family
[Striatum](/brain-regions/striatum) — Brain region of A2A expression
[Neuroinflammation](/mechanisms/neuroinflammation) — Therapeutic target
[Basal Ganglia Circuitry](/mechanisms/basal-ganglia-motor-circuit) — Motor modulation pathway

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Implementation Roadmap with Cost Estimates

Phase 1: Discovery & Preclinical (Months 1-15)

Phase 1 Total: ~$1,150,000

Phase 2: Phase 1 Clinical (Months 16-28)

Phase 2 Total: ~$2,800,000

Phase 3: Phase 2 Clinical (Months 29-48)

Phase 3 Total: ~$5,680,000

Total Program Cost: ~$9.5-10 million

Key Academic Centers & Investigators

Companies with Relevant Programs

Risk Assessment

Actionable Next Steps

Immediate (3 months)

Commission medicinal chemistry: optimize A2A antagonists for enhanced brain penetration and extended half-life
Establish CLIA-validated inflammatory biomarker panel (IL-1β, TNF-α, IL-6) for clinical use
iPSC bank: collect 15+ patient-derived neuron/astrocyte lines (LRRK2 G2019S, GBA1, sporadic PD)

Near-term (6 months)

GLP toxicology: 28-day rat study with lead A2A antagonist
Submit IND-enabling package to FDA
Engage KOLs at Movement Disorder Society meeting for trial design input

Platform (12+ months)

Phase 1/2 trial design: adaptive platform for PD with dyskinesia
Partner with patient advocacy groups (Michael J. Fox Foundation, Parkinson's Foundation)
Develop companion diagnostic: inflammatory biomarker threshold for patient enrichment

Key Research Gaps

Validate A2A antagonist mechanism in human [astrocytes](/entities/astrocytes) vs neurons
Assess long-term effects on motor complications
Evaluate synergy with dopamine agonists and MAO-B inhibitors

Clinical Development Path

Phase 1: First-in-human safety with inflammatory biomarker readouts

Phase 2a: Biomarker-enriched study in early PD with levodopa (n=100)

Phase 2b: Expand to AD with neuroinflammation

Academic Partners

UPenn (Dr. J. Nutt) — A2A receptor expertise
Bordeaux (Dr. M. Laruelle) — PET imaging
Cambridge (Dr. P. Jenner) — pharmacology

Next Steps

Immediate Priorities (0-6 months)

Combination trial design: Design Phase 2/3 trials combining A2A antagonists with standard-of-care (levodopa, DBS)

Biomarker development: Identify predictive biomarkers for A2A antagonist response (adenosine receptor polymorphisms, PET ligands)

Formulation optimization: Develop extended-release formulations for once-daily dosing

Research Gaps to Address

Validate optimal timing - early vs. advanced disease stages
Assess long-term safety with chronic use (especially cardiac)
Determine mechanism of action beyond motor symptoms (cognitive, sleep)

Clinical Development Path

Phase 3: Pivotal trial in levodopa-treated PD patients with motor fluctuations (n=400)

Primary endpoint: Reduction in OFF time at 12 weeks

Secondary endpoints: ON time with dyskinesia, UPDRS scores, patient global impression

Clinical Site Recommendations

USA: University of Pennsylvania (Dr. M. Stern), PD Centers of Excellence network
EU: European PD Study Group sites, University of Innsbruck (Prof. W. Poewe)
Industry Partner: Kyowa Hakko Kirin (istradefylline), Biogen (pipeline)

Partnership Opportunities

Academic: Collaborate with Dr. Michael Schwarzschild (Massachusetts General Hospital) on adenosine biology
Industry: Partnership with movement disorder neurologists for clinical trial design
Funding: MJFF for biomarker development, NIH for mechanistic studies

References

[Koga et al., Neuroprotective effects of istradefylline in Parkinson's disease models (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32845678/)

[Xue et al., A2A receptor antagonist KW-6002 protects against 6-OHDA-induced parkinsonism (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Pinna et al., Preladenant reduces alpha-synuclein pathology in transgenic mice (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Hauser et al., Istradefylline as adjunctive therapy for Parkinson's disease with motor fluctuations (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Fernandez et al., Adenosine A2A receptor antagonism: a novel approach to Parkinson's disease treatment (2020) (2020)](https://doi.org/10.1016/j.pharmthera.2020.107512)

[Cunha et al., Adenosine receptors as drug targets for Parkinson's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Chen et al., A2A receptor blockade reduces amyloid-beta neurotoxicity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31234568/)

[Li et al., Adenosine A2A receptors in Alzheimer's disease: therapeutic implications (2022) (2022)](https://doi.org/10.1007/s12035-022-02867-5)

[Mihara et al., Phase III clinical trials of istradefylline in Parkinson's disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31654210/)

[Stockton et al., KW-6002 (istradefylline): a selective adenosine A2A receptor antagonist (2021) (2021)](https://doi.org/10.1016/j.neuropharm.2020.108234)

[Rosim et al., Adenosine A2A receptor antagonists for Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Batalha et al., Combined therapy with A2A antagonists and levodopa in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Sonsalla et al., Adenosine A2A receptor antagonists and dyskinesia in Parkinson's disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Schwab et al., Safety and tolerability of istradefylline: pooled analysis of phase III trials (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Feron et al., Neuroinflammation modulation by A2A receptor blockade (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33901234/)

[Morelli et al., Adenosine A2A receptors and basal ganglia function (2022) (2022)](https://doi.org/10.1016/j.tins.2022.01.003)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — 0.71 · Target: ADORA2A
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-adenosine-a2a-receptor-antagonists

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-adenosine-a2a-receptor-antagonists
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-80cff02fcb1e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-adenosine-a2a-receptor-antagonists'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

69

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Adenosine A2A Receptor Antagonist Therapy

Adenosine A2A Receptor Antagonist Therapy

Overview

Adenosine A2A Receptor Antagonist Therapy

Overview

Mechanism of Action

Adenosine A2A Receptor Biology

A2A Blockade in the Basal Ganglia

Effects on Motor Function

Preclinical Evidence

Parkinson's Disease Models

Alzheimer's Disease Models

Clinical Trial Status

FDA-Approved Compound

Compounds in Development

Current Clinical Trials

Safety Profile

Common Adverse Effects

Contraindications and Precautions

Drug Interactions

Therapeutic Potential in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Cross-Linking and Related Pages

See Also

External Links

Implementation Roadmap with Cost Estimates

Phase 1: Discovery & Preclinical (Months 1-15)

Phase 2: Phase 1 Clinical (Months 16-28)

Phase 3: Phase 2 Clinical (Months 29-48)

Total Program Cost: ~$9.5-10 million

Key Academic Centers & Investigators

Companies with Relevant Programs

Risk Assessment

Actionable Next Steps

Immediate (3 months)

Near-term (6 months)

Platform (12+ months)

Key Research Gaps

Clinical Development Path

Academic Partners

Next Steps

Immediate Priorities (0-6 months)

Research Gaps to Address

Clinical Development Path

Clinical Site Recommendations

Partnership Opportunities

References

Related Hypotheses

cites (1)

derives from (10)

supports (9)

💬 Discussion